Trevi Therapeutics to Participate in Upcoming August Conferences

Rhea-AI Summary

Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming biotech conferences in August 2025. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough conditions, will be represented at Oppenheimer's 2025 Biotech in the Berkshires (August 4-6) and Stifel's 2025 Biotech Summer Summit (August 11-13).

President and CEO Jennifer Good will attend both events, with Chief Commercial Officer Farrell Simon joining for a fireside chat at the Stifel conference on August 11 at 1:00 p.m. ET.

NEW HAVEN, Conn., July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in August.

Oppenheimer's 2025 Biotech in the Berkshires
August 4 – 6, 2025, Berkshires, Massachusetts
Trevi Representative: Jennifer Good, President and CEO

Stifel's 2025 Biotech Summer Summit
August 11 – 13, 2025, Newport, Rhode Island
Fireside Chat: August 11, 1:00 p.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

About Trevi Therapeutics, Inc.    
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. 

Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. 

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. 

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn. 

Investor Contact  
Jonathan Carlson  
Trevi Therapeutics, Inc.  
(203) 654 3286  
carlsonj@trevitherapeutics.com

Media Contact  
Rosalia Scampoli  
914-815-1465  
rscampoli@marketcompr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-august-conferences-302514914.html

SOURCE Trevi Therapeutics, Inc.

FAQ

When is Trevi Therapeutics (TRVI) presenting at the Stifel Biotech Summer Summit 2025?

Trevi Therapeutics will participate in a fireside chat at 1:00 p.m. ET on August 11, 2025 at Stifel's Biotech Summer Summit in Newport, Rhode Island.

What conferences will Trevi Therapeutics (TRVI) attend in August 2025?

Trevi Therapeutics will attend Oppenheimer's Biotech in the Berkshires (August 4-6) and Stifel's Biotech Summer Summit (August 11-13, 2025).

Who will represent Trevi Therapeutics at the August 2025 conferences?

Jennifer Good, President and CEO, will attend both conferences, while Farrell Simon, Chief Commercial Officer, will join for the Stifel conference fireside chat.

What therapeutic product is Trevi Therapeutics currently developing?

Trevi Therapeutics is developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough (RCC).